News
Join our newsletter
Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.
Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ --...
Providence-Based Biotech Startup, EpiVax, Celebrates 25th Anniversary
PROVIDENCE,...
EpiVax: 25 years of Fearless Science
EpiVax is celebrating 25 years of innovative...
EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™
PROVIDENCE, RI, January 10, 2023 /PRNewswire/ --...
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
EpiVax Joins Intravacc, CEPI on Project to...
EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products
PROVIDENCE, RI, September 12, 2022 /PRNewswire/...
EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox
PROVIDENCE, RI, June 10, 2022 /PRNewswire/ --...
EpiVax and Massachusetts General Hospital Advance on T cell-Targeted Epitope Vaccine for Q Fever
PROVIDENCE, RI, May 25, 2022 /PRNewswire/ --...
EpiVax Partners with Rhode Island Foundation to Expand Charitable Giving Programs
PROVIDENCE, RI, February 8, 2022 /PRNewswire/ --...
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants
PROVIDENCE, RI, November 30, 2021 /PRNewswire/...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology
PROVIDENCE, RI, November 2021 /PRNewswire/ --...
EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ --...